AuraOne / Resources / Enterprise Intelligence

Drug-Development Diligence: A Source-Linked Workflow

An illustrative drug-development diligence workflow covering source rights, claim review, evidence gaps and handoff records—not a customer case study.

A scientist reviews molecular and clinical evidence on a large display in a modern lab
Published
April 2, 2026
Reviewed
October 25, 2026
Author
AuraOne Enterprise Intelligence team
Category
Enterprise Intelligence
Reading
4 min

Drug-development diligence often spans clinical trials, publications, regulatory records, patents, company filings, internal notes, and licensed sources.

The difficulty is not only finding a document. As the vertical-versus-general AI framework explains, choose a model only after defining the workflow and accepted evidence. The team also needs to know why the document matters, which claim it supports, who reviewed it, what assumptions remain, and which source rights apply.

This article is an editorial workflow-design example. It is not a customer case study, a public AuraOne product, or proof that AuraOne currently connects the sources named below.

Start with the current operation

Before software or a model is selected, a team should document:

  • The asset, target, company, indication, or program under review.
  • The decision the diligence work must support.
  • The current SOP, participants, volume, timing, and budget owner.
  • The public, licensed, and internal source classes the team may use.
  • The claims, assumptions, risks, gaps, and review states the output must retain.
  • The accepted handoff format and baseline for time, cost, and quality.

That current-state record determines whether the workflow is repeatable enough to standardize and whether AuraOne has a defensible role in running it.

Source boundaries

Relevant open-source interfaces may include:

A named source is an example, not a claim that an AuraOne production connector is configured. Customer systems and licensed providers require authorization, credentials, contractual access, security review, and rights appropriate to the intended use.

Assisted research can support discovery, but search results, summaries, and unverified pages should not become authoritative claims merely because they were retrieved.

A bounded workflow

A credible program workflow would follow a sequence like this:

Intake. Define the asset, diligence question, intended use, source rules, output, review policy, and acceptance criteria.

Collect. Associate allowed public and customer-provided sources with the asset record while retaining retrieval and rights context.

Review. Let qualified reviewers accept, reject, edit, or flag source material and claims. Keep disagreement and unresolved questions visible.

Prepare. Organize evidence, assumptions, risks, gaps, and next-step questions into the agreed output.

Deliver. Produce a stored, downloadable record with included source references, review states, manifest, and handoff terms.

Measure. Compare cycle time, cost, review quality, and rework with the customer's current baseline.

This workflow would support research and diligence organization. It would not provide medical advice, make clinical decisions, replace legal or regulatory review, or guarantee an investment or development outcome.

An illustrative diligence handoff

For a fictional asset review, the output could contain one row per claim: asset identifier, diligence question, source URL or licensed reference, retrieval date, relevant passage, source limitation, reviewer decision, unresolved gap and next action. Attach the permitted source set, review history and delivery manifest.

For example, a trial record and a company presentation might describe different enrollment dates. The useful output preserves both dated sources and asks a qualified reviewer to resolve the discrepancy; it does not silently choose the more favorable claim. This is a hypothetical record design, not evidence of an actual asset, clinical conclusion, investment recommendation or customer outcome.

Where automation may fit

Automation should be admitted step by step. Retrieval, extraction, deduplication, classification, and draft synthesis may be candidates when the team has a reliable benchmark and a human escalation path.

The workflow should preserve complete inputs, tool actions, reviewer corrections, and accepted outputs when the customer has authorized that use. Repeated, rights-cleared traces may later support evaluation or model specialization. That possibility is not a day-one deliverable and should never be promised before the data and economics justify it.

When this workflow is worth standardizing

A team considering this type of Enterprise Intelligence engagement should establish:

  1. A workflow it performs today.
  2. Measurable volume, cost, delay, or quality pain.
  3. Digital or capturable inputs and an objectively reviewable output.
  4. Access to required systems and legal rights to the data and traces.
  5. A named budget owner and human escalation path.
  6. Plausible economics after labor, inference, integration, and support.

Without those conditions, drug-development diligence remains an unqualified workflow idea rather than a demonstrated service. The Human Data review roles can be relevant when appropriately qualified experts and rights are available, but the program must establish the actual responsibilities.

Official source interfaces